Gubra A/S Logo

Gubra A/S

CRO & biotech accelerating peptide drug discovery for metabolic and fibrotic diseases.

GUBRA | CO

Overview

Corporate Details

ISIN(s):
DK0062266474
LEI:
254900T17RRFZONO6W53
Country:
Denmark
Address:
Hørsholm Kongevej 11 B, 2970 Hørsholm
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Gubra A/S is a specialized preclinical Contract Research Organization (CRO) and biotechnology company focused on peptide-based drug discovery for metabolic and fibrotic diseases, such as obesity, diabetes, and MASH. Founded in 2008, the company operates through two primary business areas: CRO Services, providing advanced preclinical research to accelerate partners' drug development, and Discovery & Partnerships, which develops its own pipeline of next-generation peptide therapeutics. Gubra leverages its expertise in in vivo pharmacology and peptide chemistry to streamline and advance early-stage drug development for its clients and internal projects.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Gubra A/S filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Gubra A/S

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Gubra A/S via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Poxel Logo
Develops drugs for metabolic diseases, including NASH, rare diseases, and an approved diabetes drug.
France
POXEL
PRAP Japan,Inc. Logo
A PR & communications firm building brand reputation for corporate clients in diverse industries.
Japan
2449
Predictive Oncology Inc. Logo
AI platform uses a vast tumor biobank to predict drug response and accelerate oncology discovery.
United States of America
POAI
Prime Medicine, Inc. Logo
Developing 'search and replace' gene editing therapies to treat genetic disorders.
United States of America
PRME
ProPhase Labs, Inc. Logo
Genomics, diagnostics, contract manufacturing, and OTC health & wellness solutions provider.
United States of America
PRPH
PROTHENA CORP PUBLIC LTD CO Logo
Advancing antibody-based therapies for neurodegenerative and rare amyloid diseases.
United States of America
PRTA
Psomagen, Inc. Logo
A CRO providing multiomics services & data analysis for academic, biotech, and pharma researchers.
United States of America
950200
Public Policy Holding Company, Inc. Logo
Advisory group providing public policy, government relations, and strategic communications services.
United States of America
PPHC.L
Purple Biotech Ltd. Logo
Developing cancer therapies to overcome tumor immune evasion and drug resistance.
Israel
PPBT
Qualigen Therapeutics, Inc. Logo
A clinical-stage company developing innovative treatments for rare cancers in adults and children.
United States of America
QLGN

Talk to a Data Expert

Have a question? We'll get back to you promptly.